Guggenheim Capital LLC Ardelyx, Inc. Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 111,374 shares of ARDX stock, worth $576,917. This represents 0.01% of its overall portfolio holdings.
Number of Shares
111,374
Previous 108,479
2.67%
Holding current value
$576,917
Previous $803,000
4.48%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ARDX
# of Institutions
218Shares Held
141MCall Options Held
1.08MPut Options Held
2M-
Janus Henderson Group PLC London, X021.5MShares$112 Million0.08% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$90.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$70.4 Million0.0% of portfolio
-
State Street Corp Boston, MA12.1MShares$62.9 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C38.95MShares$46.4 Million0.07% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $801M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...